Cargando…

Celecoxib Is Associated With Dystrophic Calcification and Aortic Valve Stenosis

Calcific aortic valve disease is a progressive fibrocalcific process that can only be treated with valve replacement. Cadherin-11 has recently been identified as a potential therapeutic target for calcific aortic valve disease. The already approved drug celecoxib, a cyclooxygenase-2 inhibitor, binds...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowler, Meghan A., Raddatz, Michael A., Johnson, Camryn L., Lindman, Brian R., Merryman, W. David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488810/
https://www.ncbi.nlm.nih.gov/pubmed/31061914
http://dx.doi.org/10.1016/j.jacbts.2018.12.003
Descripción
Sumario:Calcific aortic valve disease is a progressive fibrocalcific process that can only be treated with valve replacement. Cadherin-11 has recently been identified as a potential therapeutic target for calcific aortic valve disease. The already approved drug celecoxib, a cyclooxygenase-2 inhibitor, binds cadherin-11, and was investigated as a therapeutic against calcific aortic valve disease. Unexpectedly, celecoxib treatment led to hallmarks of myofibroblast activation and calcific nodule formation in vitro. Retrospective electronic medical record analysis of celecoxib, ibuprofen, and naproxen revealed a unique association of celecoxib use and aortic stenosis.